Trevogrumab: Research & Studies
Scientific evidence, clinical trials, and research findings
📌TL;DR
- •3 clinical studies cited
- •Overall evidence level: moderate
- •7 research gaps identified
Research Studies
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice
Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, Huang Y, Eckersdorff M, Rafique A, Mastaitis J, Lin C, Murphy AJ, Yancopoulos GD, Gromada J, Stitt T (2015) • Skeletal Muscle
Foundational preclinical study characterizing REGN1033 as a specific and potent myostatin antagonist. Chronic treatment of mice with REGN1033 increased muscle fiber size, muscle mass, and force production. REGN1033 prevented muscle atrophy from immobilization, glucocorticoid treatment, and hindlimb unweighting. In aged mice, REGN1033 increased muscle mass, strength, and treadmill exercise performance.
Key Findings
- REGN1033 increased muscle fiber size, mass, and force production in young mice with chronic treatment
- Prevented muscle mass loss from immobilization, dexamethasone, and hindlimb unweighting models
- Increased muscle mass recovery from pre-existing atrophy
- In aged mice, improved muscle mass, strength, and treadmill exercise performance
Limitations: Preclinical mouse study. Human translation uncertain. Doses and pharmacokinetics differ between species. Long-term effects not assessed.
GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial
Gonzalez Trotter D, Donahue S, Wynne C, Ali S, Parasoglou P, Boyapati A, Mohammadi K, Musser BJ, Meier P, Mastaitis J, Sleeman MW, Glass DJ, Gasparino E, Trejos J, Davis JD, Hirshberg B, Pordy R, Yancopoulos GD, Herman GA (2025) • Nature Communications
Two-part, randomized, placebo-controlled Phase 1 trial in 82 healthy postmenopausal women and healthy males. Tested trevogrumab (anti-GDF8) alone, garetosmab (anti-activin A) alone, and combinations. Combination blockade produced dose-dependent increases in MRI-quantitated thigh muscle volume greater than either antibody alone, establishing that GDF8 and activin A are the dominant negative regulators of muscle mass in humans. No anti-drug antibodies detected.
Key Findings
- Combination GDF8 + activin A blockade produced greater muscle volume increases than either antibody alone
- Dose-dependent increases in MRI-quantitated thigh muscle volume
- Increases in total body muscle volume and lean body mass confirmed by DXA
- Consistent effects observed after single or multiple doses
- No subjects tested positive for anti-drug antibodies post-treatment
Limitations: Phase 1 study focused on safety and PK/PD. Small sample size (n=82 across two parts). Postmenopausal women may not represent broader populations. Short treatment duration. No functional endpoints assessed.
GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates
Mastaitis JW, Gomez D, Raya JG, Li D, Min S, Stec M, Kleiner S, McWilliams T, Altarejos JY, Murphy AJ, Yancopoulos GD, Sleeman MW (2025) • Nature Communications
Preclinical study demonstrating that dual blockade of GDF8 and activin A prevents muscle loss associated with GLP-1 receptor agonists and even increases muscle mass in both obese mice and non-human primates. Muscle preservation enhanced fat loss and was metabolically beneficial, providing the preclinical rationale for the COURAGE clinical trial.
Key Findings
- Dual GDF8/activin A blockade prevented GLP-1 agonist-induced muscle loss in mice and non-human primates
- Muscle preservation enhanced fat loss beyond GLP-1 agonist alone
- Metabolic benefits observed with combined treatment
- Provided preclinical rationale for the COURAGE clinical trial design
Limitations: Animal models (mice and non-human primates). Species differences in myostatin biology. GLP-1 agonist doses and responses may differ from human clinical use. Short study duration.
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles · 30+ comparisons · 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 15+ community reports
View community protocolsExplore research gaps across all peptides → | View clinical trial pipeline →
🔍Research Gaps & Future Directions
- •COURAGE Phase 2 trial 52-week results (including weight-maintenance phase) not yet available
- •No Phase 3 registration trial initiated for any indication
- •Long-term safety of chronic myostatin blockade beyond 26-52 weeks not established
- •Optimal dosing for trevogrumab monotherapy vs combination not determined
- •Effects on muscle strength and physical function (not just mass) not yet reported from COURAGE
- •Safety of triplet therapy (trevogrumab + garetosmab + semaglutide) requires further evaluation given higher discontinuation rates and deaths in COURAGE
- •Head-to-head comparison with bimagrumab not available
Research Overview#
Trevogrumab has a growing evidence base spanning preclinical studies in mice and non-human primates, a Phase 1 trial in humans, and an ongoing Phase 2 trial (COURAGE) in obesity. The research program has been conducted primarily by Regeneron Pharmaceuticals, with both the preclinical and clinical studies published in high-impact journals.
Preclinical Evidence#
REGN1033 Mouse Studies (Skeletal Muscle 2015)#
Latres et al. (PMID 26457176) provided the foundational characterization of REGN1033 as a myostatin antagonist:
Key Results:
| Model | Effect of REGN1033 |
|---|---|
| Young mice (chronic dosing) | Increased muscle fiber size, mass, and force |
| Immobilization atrophy | Prevented muscle mass loss |
| Glucocorticoid (dexamethasone) atrophy | Prevented muscle mass loss |
| Hindlimb unweighting | Prevented muscle mass loss |
| Recovery from atrophy | Enhanced muscle mass regain |
| Aged mice | Increased mass, strength, and treadmill performance |
The study established that REGN1033 is a specific and potent myostatin antagonist with broad utility across multiple atrophy models.
GLP-1 Combination Preclinical Data (Nature Communications 2025)#
Mastaitis et al. (PMID 40360507) demonstrated that dual blockade of GDF8 and activin A in mice and non-human primates prevented GLP-1 agonist-induced muscle loss while enhancing fat loss. This study provided the direct preclinical rationale for testing trevogrumab with semaglutide in humans.
Phase 1 Clinical Trial#
Postmenopausal Women (Nature Communications 2025)#
Gonzalez Trotter et al. (PMID 40360471) conducted a two-part Phase 1 trial in 82 subjects:
- Part I: Single-dose trevogrumab alone, garetosmab alone, or combinations in healthy postmenopausal women
- Part II: Multiple-dose administration in postmenopausal women and healthy males
Key Findings:
- Combination blockade produced dose-dependent MRI-quantitated thigh muscle volume increases
- Greater muscle gains with combination than either antibody alone
- Total body muscle and lean mass increases confirmed by DXA
- Well-tolerated with no anti-drug antibodies detected
This was the first clinical demonstration that GDF8 and activin A are the dominant negative regulators of human muscle mass.
Phase 2 COURAGE Trial#
The COURAGE trial (NCT06299098) is the pivotal ongoing study for trevogrumab in obesity. This randomized, double-blind study enrolled 999 patients with obesity (BMI >=30) across four treatment arms.
26-Week Results (Presented at EASD 2025)#
| Outcome | Semaglutide | + Trevo 200 mg | + Trevo 400 mg | + Trevo 400 mg + Gareto |
|---|---|---|---|---|
| Weight loss (lbs) | -23.0 | -21.6 | -24.8 | -30.0 |
| Weight loss (%) | -10.4% | -9.9% | -11.3% | -13.2% |
| Fat mass loss (lbs) | -15.3 | -16.9 | -18.9 | -25.4 |
| Lean mass loss (lbs) | -7.9 | -3.7 | -4.2 | -2.0 |
| Lean mass preserved | Reference | 50.8% | 51.3% | 80.9% |
The results demonstrate that trevogrumab preserves approximately half of the lean mass that would otherwise be lost during semaglutide treatment, while also increasing fat loss. The triplet therapy achieved even greater lean mass preservation (80.9%) and fat loss enhancement.
Evidence Quality Assessment#
| Criterion | Assessment | Details |
|---|---|---|
| Preclinical evidence | Strong | Multiple atrophy models, NHP data |
| Phase 1 clinical | Published | Nature Communications 2025, n=82 |
| Phase 2 clinical | Interim data | COURAGE 26-week results at EASD |
| Publication quality | High | Nature Communications (2 papers), Skeletal Muscle |
| Body composition effects | Promising | 50% lean mass preservation in dual therapy |
| Functional outcomes | Unknown | Not yet reported from COURAGE |
| Safety profile | Favorable (dual) | Triplet had higher discontinuation rates |
| Regulatory status | Investigational | No approval applications filed |
Critical Assessment#
Trevogrumab addresses a genuine clinical need: muscle preservation during GLP-1 agonist-induced weight loss. The COURAGE data are encouraging, showing that selective myostatin blockade can preserve lean mass while enhancing fat loss. However, several limitations remain:
- 26-week data only: The full 52-week COURAGE results, including the weight-maintenance phase, have not been reported
- No functional endpoints: Whether preserved lean mass translates to improved physical function is unknown (a lesson from bimagrumab's IBM failure)
- Triplet safety signals: The trevogrumab + garetosmab + semaglutide combination had 28.3% discontinuation and two deaths, raising questions about the triplet approach
- Conference data: COURAGE results are from conference presentations, not peer-reviewed publications
Related Reading#
Frequently Asked Questions About Trevogrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.